封面
市場調查報告書
商品編碼
1728154

多囊性腎病市場-全球產業規模、佔有率、趨勢、機會和預測,按類型、按治療類型、按最終用戶、按地區和競爭進行細分,2020 年至 2030 年

Polycystic Kidney Disease Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Treatment Type, By End User, By Region and Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球多囊性腎病變 (PKD) 市值為 5.0239 億美元,預計到 2030 年將達到 7.5869 億美元,預測期內複合年成長率為 7.11%。 PKD 是一種遺傳性疾病,其特徵是腎臟中長出充滿液體的囊腫,導致腎臟逐漸腫大並最終導致腎衰竭。全球範圍內常染色體顯性和隱性 PKD 盛行率的上升、診斷能力的提高以及研究投入的增加推動了市場擴張。精準醫療的進步使得基於個別基因圖譜的更有針對性的治療方法成為可能。患者數量的不斷成長,加上醫療保健專業人員意識的提高以及早期檢測的基因篩檢的結合,刺激了對有效治療方案的需求。製藥公司和研究機構越來越注重開發創新干預措施,以延緩疾病進展並改善患者預後,從而推動市場成長。

市場概覽
預測期 2026-2030
2024年市場規模 5.0239億美元
2030年市場規模 7.5869億美元
2025-2030 年複合年成長率 7.11%
成長最快的領域 常染色體顯性多囊性腎病變(ADPKD)
最大的市場 北美洲

關鍵市場促進因素

多囊性腎病變(PKD)盛行率不斷上升

主要市場挑戰

治療費用高昂

主要市場趨勢

遺傳學研究的進展

目錄

第 1 章:產品概述

第2章:研究方法

第3章:執行摘要

第4章:全球多囊性腎病變市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依類型(常染色體顯性多囊性腎病變 (ADPKD)、常染色體隱性多囊性腎病變 (ARPKD)、其他)
    • 依治療類型(診斷、藥物/療法)
    • 按最終使用者(醫院和診所、門診護理中心、其他)
    • 按地區
    • 按公司分類(2024)
  • 市場地圖
    • 按類型
    • 按治療類型
    • 按最終用戶
    • 按地區

第5章:亞太多囊腎市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按類型
    • 按治療類型
    • 按最終用戶
    • 按國家/地區
  • 亞太地區:國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第6章:歐洲多囊性腎病市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲:國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第7章:北美多囊性腎病變市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美:國家分析
    • 美國
    • 墨西哥
    • 加拿大

第8章:南美多囊性腎病變市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲:國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第9章:中東和非洲多囊性腎病市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA:國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第10章:市場動態

  • 驅動程式
  • 挑戰

第 11 章:市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 12 章:全球缺鐵性貧血:SWOT 分析

第 13 章:波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章:競爭格局

  • Otsuka Pharmaceuticals
  • Camber Pharmaceuticals
  • Apotex Corp
  • Ascend Laboratories
  • Par Pharmaceuticals
  • Teva Pharmaceutical Industries
  • Merck KGA
  • Accord Healthcare
  • Pfizer Inc.
  • PD-Rx Pharmaceuticals, Inc

第 15 章:策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 16902

The Global Polycystic Kidney Disease (PKD) Market was valued at USD 502.39 million in 2024 and is projected to reach USD 758.69 million by 2030, growing at a CAGR of 7.11% during the forecast period. PKD is a genetic condition characterized by the growth of fluid-filled cysts in the kidneys, leading to progressive kidney enlargement and eventual renal failure. Market expansion is being propelled by a rising global prevalence of both autosomal dominant and recessive forms of PKD, improved diagnostic capabilities, and increased research investment. Advancements in precision medicine are enabling more targeted therapeutic approaches based on individual genetic profiles. The growing patient population, combined with heightened awareness among healthcare professionals and the integration of genetic screening for early detection, has stimulated demand for effective treatment options. Pharmaceutical companies and research institutions are increasingly focused on developing innovative interventions to delay disease progression and enhance patient outcomes, thereby fueling market growth.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 502.39 Million
Market Size 2030USD 758.69 Million
CAGR 2025-20307.11%
Fastest Growing SegmentAutosomal Dominant Polycystic Kidney Disease (ADPKD)
Largest MarketNorth America

Key Market Drivers

Increasing Prevalence of Polycystic Kidney Disease (PKD)

The rising incidence of PKD worldwide is a major growth catalyst for the market. As a hereditary condition, PKD has seen growing diagnosis rates due to enhanced screening and genetic testing. Autosomal dominant PKD (ADPKD) affects approximately 1 in every 400 to 1,000 people, while autosomal recessive PKD (ARPKD) occurs in 1 in 20,000 to 40,000 individuals. With healthcare systems adopting more robust diagnostic practices, particularly among individuals with a family history of the disease, the patient pool is expanding. Increased awareness among clinicians and the general public has led to earlier detection and intervention, promoting demand for both supportive and disease-modifying therapies. As the affected population grows, pharmaceutical investment in PKD-focused research and treatment innovation is also accelerating.

Key Market Challenges

High Treatment Costs

The high cost associated with PKD treatment continues to hinder broader access and adoption of advanced therapies. Management of PKD often requires lifelong monitoring, imaging, nephrology consultations, and eventually renal replacement therapies such as dialysis or kidney transplantation in advanced cases. Limited availability of approved and cost-effective medications further compounds the financial burden on patients. Targeted drugs that are in clinical development or recently approved tend to be expensive, making them inaccessible to many, particularly in low-resource settings. Additionally, the long-term costs of managing disease progression and complications place pressure on both patients and healthcare systems, posing a substantial challenge to the market's growth and equitable treatment access.

Key Market Trends

Advancements in Genetic Research

Ongoing progress in genetic research is significantly influencing the PKD treatment landscape. Identification of mutations in genes such as PKD1 and PKD2 has facilitated the development of personalized treatment strategies and innovative therapies targeting the molecular mechanisms driving cyst formation. Gene-editing technologies and pharmacogenomics are enabling the design of more effective and potentially curative interventions. Furthermore, the discovery of reliable biomarkers is supporting early diagnosis, disease monitoring, and patient stratification for clinical trials. These advancements are streamlining drug development and paving the way for precision medicine in PKD care. Collaborations among geneticists, pharmaceutical companies, and advocacy groups are accelerating these efforts, increasing the pace at which research translates into clinical practice and market offerings.

Key Market Players

  • Otsuka Pharmaceuticals
  • Camber Pharmaceuticals
  • Apotex Corp
  • Ascend Laboratories
  • Par Pharmaceuticals
  • Teva Pharmaceutical Industries
  • Merck KGA
  • Accord Healthcare
  • Pfizer Inc.
  • PD-Rx Pharmaceuticals, Inc

Report Scope:

In this report, the Global Polycystic Kidney Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Polycystic Kidney Disease Market, By Type:

  • Autosomal dominant polycystic kidney disease (ADPKD)
  • Autosomal recessive polycystic kidney disease (ARPKD)
  • Others

Global Polycystic Kidney Disease Market, By Treatment Type:

  • Diagnosis
  • Drug/Therapy

Global Polycystic Kidney Disease Market, By End User:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Global Polycystic Kidney Disease Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Polycystic Kidney Disease Market.

Available Customizations:

Global Polycystic Kidney Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Polycystic Kidney Disease Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Type (Autosomal dominant polycystic kidney disease (ADPKD), Autosomal recessive polycystic kidney disease (ARPKD), Others)
    • 4.2.2. By Treatment Type (Diagnosis, Drug/Therapy)
    • 4.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 4.2.4. By Region
    • 4.2.5. By Company (2024)
  • 4.3. Market Map
    • 4.3.1. By Type
    • 4.3.2. By Treatment Type
    • 4.3.3. By End User
    • 4.3.4. By Region

5. Asia Pacific Polycystic Kidney Disease Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type
    • 5.2.2. By Treatment Type
    • 5.2.3. By End User
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Polycystic Kidney Disease Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Type
        • 5.3.1.2.2. By Treatment Type
        • 5.3.1.2.3. By End User
    • 5.3.2. India Polycystic Kidney Disease Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Type
        • 5.3.2.2.2. By Treatment Type
        • 5.3.2.2.3. By End User
    • 5.3.3. Australia Polycystic Kidney Disease Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Type
        • 5.3.3.2.2. By Treatment Type
        • 5.3.3.2.3. By End User
    • 5.3.4. Japan Polycystic Kidney Disease Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Type
        • 5.3.4.2.2. By Treatment Type
        • 5.3.4.2.3. By End User
    • 5.3.5. South Korea Polycystic Kidney Disease Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Type
        • 5.3.5.2.2. By Treatment Type
        • 5.3.5.2.3. By End User

6. Europe Polycystic Kidney Disease Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Treatment Type
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Polycystic Kidney Disease Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Treatment Type
        • 6.3.1.2.3. By End User
    • 6.3.2. Germany Polycystic Kidney Disease Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Treatment Type
        • 6.3.2.2.3. By End User
    • 6.3.3. Spain Polycystic Kidney Disease Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Treatment Type
        • 6.3.3.2.3. By End User
    • 6.3.4. Italy Polycystic Kidney Disease Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Type
        • 6.3.4.2.2. By Treatment Type
        • 6.3.4.2.3. By End User
    • 6.3.5. United Kingdom Polycystic Kidney Disease Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Type
        • 6.3.5.2.2. By Treatment Type
        • 6.3.5.2.3. By End User

7. North America Polycystic Kidney Disease Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Treatment Type
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Polycystic Kidney Disease Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Treatment Type
        • 7.3.1.2.3. By End User
    • 7.3.2. Mexico Polycystic Kidney Disease Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Treatment Type
        • 7.3.2.2.3. By End User
    • 7.3.3. Canada Polycystic Kidney Disease Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Treatment Type
        • 7.3.3.2.3. By End User

8. South America Polycystic Kidney Disease Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Treatment Type
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Polycystic Kidney Disease Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Treatment Type
        • 8.3.1.2.3. By End User
    • 8.3.2. Argentina Polycystic Kidney Disease Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Treatment Type
        • 8.3.2.2.3. By End User
    • 8.3.3. Colombia Polycystic Kidney Disease Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Treatment Type
        • 8.3.3.2.3. By End User

9. Middle East and Africa Polycystic Kidney Disease Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Treatment Type
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Polycystic Kidney Disease Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Treatment Type
        • 9.3.1.2.3. By End User
    • 9.3.2. Saudi Arabia Polycystic Kidney Disease Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Treatment Type
        • 9.3.2.2.3. By End User
    • 9.3.3. UAE Polycystic Kidney Disease Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Treatment Type
        • 9.3.3.2.3. By End User

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Iron Deficiency Anemia: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Otsuka Pharmaceuticals
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (In case of listed)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Camber Pharmaceuticals
  • 14.3. Apotex Corp
  • 14.4. Ascend Laboratories
  • 14.5. Par Pharmaceuticals
  • 14.6. Teva Pharmaceutical Industries
  • 14.7. Merck KGA
  • 14.8. Accord Healthcare
  • 14.9. Pfizer Inc.
  • 14.10. PD-Rx Pharmaceuticals, Inc

15. Strategic Recommendations

16. About Us & Disclaimer